Saxenda was the first GLP-1 approved specifically for chronic weight management in non-diabetic patients, while Ozempic entered the weight loss conversation as an off-label use of a diabetes medication
Findings in context of the broader literature Our results are consistent overall with a post hoc analysis of pooled SUSTAIN and PIONEER data, which also showed that the effect of semaglutide vs comparators on MACE was largely consistent across different CV subgroups [35]
However, it's essential to consult with a healthcare professional before using any medication to ensure it's appropriate for your situation
But the report also noted that half of seniors who would qualify for obesity coverage already have access to the drugs for other conditions
Your safety and comfort are our top priorities, and we take every measure to ensure both are upheld
Investigators from the National Health and Nutrition Examination Survey estimate that 136.8 million adults met the criteria for at least one of three approved indications for semaglutide diabetes, weight management, or secondary cardiovascular disease prevention: